Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biohit OyjLTS:0DRP +0.37%66 EV-to-EBITDA is 10.13 as of Aug. 10, 2026, which is 5% above its 10-year median of 9.66. GuruFocus rates LTS:0DRP with a GF Score™ of 66/100 and a GF Value™ of €2.77 (Fairly Valued). The stock has 4 warning signs investors should review. Among 516 Medical Devices & Instruments companies, Biohit Oyj ranks better than 66.47% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Biohit Oyj's enterprise value is €37.49 Mil.
Biohit Oyj's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €3.70 Mil. Therefore, Biohit Oyj's EV-to-EBITDA for today is 10.13.
The historical rank and industry rank for Biohit Oyj's EV-to-EBITDA or its related term are showing as below:
LTS:0DRP'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -209.74 Med: 9.66 Max: 67.58
Current: 10.13
During the past 13 years, the highest EV-to-EBITDA of Biohit Oyj was 67.58. The lowest was -209.74. And the median was 9.66.
LTS:0DRP's EV-to-EBITDA is ranked better than 66.47% of 516
companies
in the Medical Devices & Instruments industry
Industry Median: 14.76
vs LTS:0DRP: 10.13
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Biohit Oyj's share price for today is €2.74.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Biohit Oyj's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.180.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Biohit Oyj's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0DRP vs ABT, SYK, MDT: EV-to-EBITDA Comparison
For the Medical Devices subindustry, Biohit Oyj's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biohit Oyj EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Biohit Oyj's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Biohit Oyj's EV-to-EBITDA falls into.
Biohit Oyj's current Enterprise Value is €37.49 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Biohit Oyj's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €3.70 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biohit Oyj (LTS:0DRP) has a EV-to-EBITDA of 10.13 as of Aug. 10, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Biohit Oyj. This is near median its historical median of 9.66. According to the industry distribution chart, Biohit Oyj ranks #173 out of 516 companies in the Medical Devices & Instruments industry, placing it in the top 33.5%.
Is Biohit Oyj's EV-to-EBITDA too high?
Biohit Oyj's current EV-to-EBITDA of 10.13 is near median its 10-year median of 9.66. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.76. Biohit Oyj's value of 10.13 is 31.4% below this industry median. Based on the distribution chart, Biohit Oyj ranks #173 out of 516 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Biohit Oyj has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biohit Oyj's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Biohit Oyj ranks #173 out of 516 companies for EV-to-EBITDA. This puts Biohit Oyj in the upper half of its industry. The industry median EV-to-EBITDA is 14.76. Biohit Oyj's value of 10.13 is 31.4% below this benchmark. While the company's 10-year median is 9.66 vs. the industry median of 14.76, Biohit Oyj has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.76, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biohit Oyj's current EV-to-EBITDA of 10.13 is 31.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Biohit Oyj. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biohit Oyj's current EV-to-EBITDA is 10.13, which is near median its own 10-year median of 9.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biohit Oyj stock overvalued right now?
Based on GuruFocus' analysis, Biohit Oyj (LTS:0DRP) is currently considered Fairly Valued. The stock's GF Value™ is €2.77, compared to a current price of €2.74 — trading 1.1% below its estimated fair value. The current EV-to-EBITDA is 10.13, which is near median its 10-year median of 9.66 and 31.4% below the Medical Devices & Instruments industry median of 14.76. Biohit Oyj's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Biohit Oyj (LTS:0DRP), the current EV-to-EBITDA is 10.13 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biohit Oyj (LTS:0DRP) Overvalued in 2026?
Based on GuruFocus' analysis, Biohit Oyj stock appears to be undervalued.
The current stock price of €2.74 is trading 1.1% below its estimated GF Value™ of €2.77.
GuruFocus considers Biohit Oyj to be Fairly Valued.
Key valuation signals for LTS:0DRP:
EV-to-EBITDA: 10.13 (near median its 10-year median of 9.66)
GF Value™: €2.77 vs. price of €2.74 (1.1% below fair value)
Industry Position: 31.4% below the Medical Devices & Instruments median (#173 of 516)
No single metric tells the full story. See the LTS:0DRP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biohit Oyj is a globally operating Finnish biotechnology company that develops diagnostic and other health products. Its products include GastroPanel quick test assesses the structure and function of the stomach lining; ColonView quick test is an immunochemical fecal occult blood test (FIT) developed; Acetium capsules protect the stomach lining from carcinogenic acetaldehyde, especially in people with acid-free stomachs. The company's product portfolio consists of diagnostic tests, analysis systems, products binding carcinogenic acetaldehyde into a harmless compound and monoclonal antibodies.
66GF Score
Get the complete analysis for LTS:0DRP
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0DRP has been successfully added to your 
